Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.26 (
GSK
)
6,788
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
G-protein coupled receptor kinases (GRKs) constitute a serine/threonine kinase family playing a major role in agonist-induced phosphorylation and desensitization of G-protein coupled receptors. Recently, GRK2 and GRK5 have been demonstrated to phosphorylate alpha-synuclein (Ser129) and other synuclein isoforms. We studied colocalization of GRK2, GRK5, alpha-synuclein, and tau in neurodegenerative disorders characterized by fibrillary tau inclusions and/or alpha-synuclein-enriched Lewy bodies. We found that Lewy bodies were negative for both GRK2 and GRK5 in
Lewy body disease
(
LBD
) and
LBD
mixed with Alzheimer disease (AD +
LBD
). Instead, GRK2 but not GRK5 colocalized with 40% to 50% of neurofibrillary tangles in AD +
LBD
and AD brains. In disorders with less prominent alpha-synucleinopathy, neuronal and glial fibrillary tau deposits known to contain distinct subsets of tau isoforms were also positive for GRK2. These deposits included tufted astrocytes and coiled bodies in progressive supranuclear palsy, astrocytic plaques in corticobasal degeneration, and Pick bodies in Pick disease. In addition, paired helical filaments isolated from AD and AD +
LBD
brains were found to immunogold-label for GRK2, suggesting that GRK2 could be a potential
tau kinase
associated with fibrillary tau. Our studies indicate that GRK2 is a novel component of neuronal and glial fibrillary tau deposits with no preference in tau isoform binding. GRK2 may play a role in hyperphosphorylation of tau in tauopathies.
...
PMID:Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles. 1714 90
The somatodendritic accumulation of hyperphosphorylated tau proteins is an early event preceding the appearance of neurofibrillary tangles (NFT) in Alzheimer's disease (AD) and might be necessary for their formation. Glycogen synthase kinase-3beta (GSK-3beta) is a physiological kinase for tau that generates many tau phosphorylation sites identified in NFT and in other tau-positive inclusions. We have studied the cellular distribution and the expression of the active form of
GSK
-3beta (GSK-3 pTyr216) in AD patients, in argyrophilic grain disease and in diffuse
Lewy body disease
. By Western blotting analysis, a significant increase in the level of
GSK
-3 (pTyr216) was observed in the frontal cortex of AD patients. A population of neurones showed a somatodendritic accumulation of
GSK
-3 (pTyr216) but not of the inactive form of
GSK
-3beta (GSK-3 pSer9). Most of these
GSK
-3 (pTyr216)-positive cells were positive for six different phosphotau epitopes known to be generated by
GSK
-3beta. By using a quadruple labelling method using
GSK
-3 (pTyr216) and phosphotau immunolabelling combined with Gallyas and DAPI staining, we examined neurones containing a somatodendritic
GSK
-3 (pTyr216) immunoreactivity at different stages of neurodegeneration. A majority of neurones at the pretangle stage without Gallyas-positive inclusions were
GSK
-3 (pTyr216) positive and this
GSK
-3 (pTyr216) immunoreactivity remained in most cells containing Gallyas and phosphotau-positive inclusions excepted in extracellular NFT. A
GSK
-3 (pTyr216) immunoreactivity was present in argyrophilic grains but not in cortical Lewy bodies. These results directly suggest that the activity of
GSK
-3beta is increased in AD and that somatodendritic accumulation and activation of
GSK
-3beta is an early event preceding and accompanying the formation of NFT and of other tau-positive inclusions.
...
PMID:Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. 1723 7